What is claimed is:

1. A bispecific monoclonal antibody comprising:

a) a first antigen-binding site that specifically binds human vascular endothelial growth factor (VEGF), and

b) a second antigen-binding site that specifically binds human delta-like 4 ligand (DLL4),

wherein the first antigen-binding site comprises a heavy chain CDR1 comprising NYWMH (SEQ ID NO:17), a heavy chain CDR2 comprising DINPSNGRTSYKEKFKR (SEQ ID NO:18), and a heavy chain CDR3 comprising HYDDKYYPLMDY (SEQ ID NO:19);

wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13) or AYYIH (SEQ ID NO:79), a heavy chain CDR2 comprising $YIX_1X_2YX_3X_4ATNYNQKFKG$ (SEQ ID NO:80), wherein X_1 is serine or alanine, X_2 is asparagine, serine, or glycine, X_3 is asparagine or lysine, and X_4 is arginine, glycine, or aspartic acid , and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16); and

wherein both the first and second antigen-binding sites comprise a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and a light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).

2. The bispecific antibody of claim 1, wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising YISNYNRATNYNQKFKG (SEQ ID NO:65), YIANYNRATNYNQKFKG (SEQ ID NO:14), YISSYNGATNYNQKFKG (SEQ ID NO:15), or YIAGYKDATNYNQKFKG (SEQ ID NO:59), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).

3. The bispecific antibody of claim 1 or claim 2, which comprises:

(a) a first heavy chain variable region having at least 90% sequence identity to SEQ ID NO:11;

(b) a second heavy chain variable region having at least 90% sequence identity to SEQ ID NO: 64, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:58, ; and

(c) a first and a second light chain variable region having at least 90% sequence identity to SEQ ID NO:12.

4. The bispecific antibody of any one of claims 1-3, which is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, an IgG1 antibody, or an IgG2 antibody.

5. The bispecific antibody of any one of claims 1-3, which comprises a first human IgG2 constant region with amino acid substitutions at positions corresponding to positions 249 and 288 of SEQ ID NO:42, wherein the amino acids are replaced with glutamate or aspartate, and a second human IgG2 constant region with amino acid substitutions at positions corresponding to positions 236 and 278 of SEQ ID NO:42, wherein the amino acids are replaced with lysine.

6. The bispecific antibody of any one of claims 1-5, which:
   (i) inhibits binding of VEGF to at least one VEGF receptor;
   (ii) inhibits binding of DLL4 to at least one Notch receptor;
   (iii) inhibits Notch signaling; and/or
   (iv) modulates angiogenesis.

7. A bispecific antibody that specifically binds human VEGF and human DLL4, comprising:
   (a) a heavy chain of SEQ ID NO:7;
   (b) a heavy chain of SEQ ID NO: 62, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:56 ; and
   (c) two light chains of SEQ ID NO:8.

8. A bispecific antibody selected from the group consisting of 219R45-MB-21R83, 219R45-MB-21M18, 219R45-MB-21R79, and 219R45-MB-21R75.

9. An isolated monoclonal antibody that specifically binds human VEGF, which comprises:
   (a) a heavy chain CDR1 comprising NYWMH (SEQ ID NO:17), a heavy chain CDR2 comprising DINPSNGRTSYKEKFKR (SEQ ID NO:18), and a heavy chain CDR3 comprising HYDDKYYPLMDY (SEQ ID NO:19); and

(b) a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and a light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).

10. The antibody of claim 9, which comprises:

(a) a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:11; and

(b) a light chain variable region having at least 90% sequence identity to SEQ ID NO:12.

11. The antibody of claim 9, which comprises:

(a) a heavy chain comprising SEQ ID NO:49; and

(b) a light chain comprising SEQ ID NO:8.

12. The antibody of any one of claims 9-11, which inhibits binding of VEGF to at least one VEGF receptor.

13. An isolated monoclonal antibody that specifically binds human DLL4, which comprises:

a) a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising, YISNYNRATNYNQKFKG (SEQ ID NO:65),YIANYNRATNYNQKFKG (SEQ ID NO:14), or YIAGYKDATNYNQKFKG (SEQ ID NO:59) and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16); and

b) a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and a light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).

14. The antibody of claim 13, which comprises:

(a) a heavy chain variable region comprising SEQ ID NO: 64, SEQ ID NO:10, or SEQ ID NO:58; and

(b) a light chain variable region comprising SEQ ID NO:12.

15. The antibody of any one of claims 9-14, which is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, a bispecific antibody, an IgG1 antibody, an IgG2 antibody, or an antibody fragment comprising an antigen-binding site.

16. A pharmaceutical composition comprising the antibody of any one of claims 1-15 and a pharmaceutically acceptable carrier.

17. A cell comprising or producing the antibody of any one of claims 1-15.

18. An isolated polynucleotide molecule comprising a polynucleotide that encodes the antibody of any one of claims 1-15.

19. A vector comprising the polynucleotide of claim 18.

20. A cell comprising the polynucleotide of claim 18.

21. A polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:62, SEQ ID NO:63, and SEQ ID NO:64.

22. Use of the antibody of any one of claims 1-15 in the manufacture of a medicament for treatment of cancer.

23. The use of the antibody of claim 22, wherein the cancer is selected from the group consisting of colon cancer, ovarian cancer, pancreatic cancer and gastrointestinal cancer.

24. Use of the antibody of any one of claims 1-15 in the manufacture of a medicament for inhibiting growth of a tumor.

25. The use of the antibody of claim 24, wherein the tumor is selected from the group consisting of colon tumor, ovarian tumor, pancreatic tumor and gastrointestinal tumor.

26. The use of the antibody of any one of claims 22-25, wherein the use comprises the antibody and at least one additional therapeutic agent.

27. The use of the antibody of claim 26, wherein the at least one additional therapeutic agent is a chemotherapeutic agent.

28. The use of the antibody of claim 26, wherein the at least one additional therapeutic agent is a second antibody.

29. The antibody of any one of claims 1-15 for use in the treatment of cancer.

30. The antibody of claim 29, wherein the cancer is selected from the group consisting of colon cancer, ovarian cancer, pancreatic cancer and gastrointestinal cancer.

31. The antibody of any one of claims 1-15 for use in inhibiting growth of a tumor.

32. The antibody of claim 31, wherein the tumor is selected from the group consisting of colon tumor, ovarian tumor, pancreatic tumor and gastrointestinal tumor.

33. The antibody of any one of claims 29-32, wherein the treatment of cancer or the inhibiting growth of a tumor comprises the use of at least one additional therapeutic agent.

34. The antibody of claim 33, wherein the at least one additional therapeutic agent is a chemotherapeutic agent.

35. The antibody of claim 33, wherein the at least one additional therapeutic agent is a second antibody.

36. An *in* vitro method for the production of an antibody, comprising expressing at least one polynucleotide of claim 18 in a cell.

37. The antibody of any one of claims 1-15 for use in therapy.